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Abstract
Purpose The European Association of Urology (EAU) guidelines for penile cancer (PC) are exclusively based on retrospec-
tive studies and have low grades of recommendation. The aim of this study was to assess the adherence to guidelines by 
investigating the management strategies for primary tumours and inguinal lymph nodes.
Methods We retrospectively reviewed the clinical charts of 176 PC patients who underwent surgery in eight European centres 
from 2010 to 2016. The stage and grade were assessed according to the 2009 AJCC–UICC TNM classification system. To 
assess adherence rates, we compared theoretical and practical adherence to the EAU guidelines.
Results Overall, 176 patients were enrolled. Partial amputation was the most frequent surgical approach (39%). 53.7% of 
tumours were stage Tis-T1b and the remaining 46.3% were stage T2-T4. Palpable lymph nodes were detected in 30.1% of 
patients and 45.1% underwent lymphadenectomy (LY). A sizeable group of tumours (43.2%) were N0. For primary treat-
ment, adherence to the EAU guidelines was good (66%). In non-adherent cases, reasons for discrepancy were patient’s choice 
(17%), surgeon’s preference (36%), and other causes (47%). For LY, the guideline adherence was 70%, with either patient’s 
or surgeon’s choice or other causes accounting for discrepancy in 28, 20, and 52% of non-adherent cases, respectively.
Conclusion Adherence to the EAU guidelines for PC was quite high across the eight European centres involved in the study. 
This notwithstanding, strategies for further improvement should be developed and evenly adopted.
Keywords Penile cancer · Adherence · EAU guidelines · Lymphadenectomy · Partial amputation · Total amputation
Introduction
Penile cancer (PC) is a rare malignancy and a potentially 
mutilating disease for men. In the United States and Western 
countries, it accounts for 0.4–0.6% of all malignancies (Clark 
et al. 2013). The major risk factor for PC is an uncircumcised 
penis (Maden et al. 1993). Other factors include HPV infec-
tion, smoke, and low socio-economic status (Rubin et al. 
2001; Harish and Ravi 1995; Daling et al. 2005). About 95% 
of penile cancers are squamous cell carcinomas (SCC) and 
can develop anywhere on the penis (Christodoulidou et al. 
2015). Most commonly, these tumours appear as a lump or 
nodule (47%), an ulcer (35%), an erythematous lesion (17%), 
or an incidental finding at circumcision (0.7%) (Hernandez 
et al. 2008). If treated at an early stage, PC has a cure rate 
of 80%. Pathologic stage or grade of the primary tumour 
and subsequent locoregional lymph node metastasis drive 
survival, with node-positive patients having 5-year survival 
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rates ranging from 20 to 80% (Pandey et al. 2006). The opti-
mal treatment for primary tumour depends on lesion’s size, 
location, and possibility of oncological radicality preserv-
ing both quality of life and sexual satisfaction. Since PC 
is a rare disease, the treatment is not always uniform and 
often depends on surgeon’s experience and patient’s prefer-
ences. For example, radical inguinal lymph node dissection 
(ILND) is the standard of care for node-positive patients and 
is potentially curative in half of the cases (McDougal 2005); 
however, its complexity and associated high degree of mor-
bidity (wound healing and lymphoedema) often discourage 
use (Thuret et al. 2011). Theoretically, guidelines should 
provide evidence-based guidance to physicians and patients 
alike. Although following established guidelines has been 
found to improve patient outcomes and enhance consistency 
of practices, some studies on solid cancer treatment report 
extremely variable adherence rates, ranging from 40 to 99% 
(Heins et al. 2016). The aim of this study was to evaluate 
adherence to the EAU guidelines in a multicentre series of 
patients surgically treated for penile cancer.
Materials and methods
We retrospectively reviewed the clinical charts of 176 PC 
patients who underwent surgery in 8 European centres from 
2010 to 2016. The study was approved by the Ethics Com-
mittee of each participating institution and all the procedures 
were performed in accordance with the Declaration of Hel-
sinki. Information on demographics, patients’ comorbidities, 
circumcision, site of primary lesion, local therapy, lymph 
node management, and histopathological data was collected 
and analysed. Staging was as per the 2009 AJCC–UICC 
TNM classification system and was performed with a com-
bination of physical examination and CT and/or MRI. Treat-
ment of the primary tumour and the decision to proceed to 
inguinal lymph node dissection were established according 
to local protocols based on the 2009 EAU guidelines. For 
patients with penile carcinoma in situ (CIS), the European 
Association of Urology recommends topical chemotherapy 
with 5% fluorouracil and imiquimod (Alnajjar et al. 2012). 
For Ta/T1 lesions, laser ablation is a valid treatment (Colec-
chia et al. 2009). For penile glans tumours, glans resurfac-
ing and glansectomy are preferred (Pizzocaro et al. 2010). 
When tumours extend into the corporeal bodies, urethra, 
and adjacent structures (T2–T4), partial penectomy provides 
excellent oncologic control (Opjordsmoen and Fossa 1994). 
When a negative margin cannot be achieved, or a large fun-
gating tumour is present, total amputation with perineal ure-
throstomy is recommended (Garaffa et al. 2009). As regards 
inguinal lymph node management, patients with clinically 
node-negative (cN0) pTis, pTa, and pT1a tumours are at 
low risk of inguinal metastasis and are suitable candidates 
for observation. For patients with intermediate-to high-risk 
tumours (pT1b, T2–T4), either modified inguinal lymph 
node dissection (ILND) or dynamic sentinel node biopsy 
(DSLNB) is recommended (Hughes et al. 2010). Patients 
with clinically positive lymph nodes (cN1/cN2) are at high 
risk of metastatic disease and radical ILND is in order. 
Enlarged fixed inguinal lymph nodes (cN3) require multi-
modal treatment by chemotherapy followed by radical ILND 
in clinically responsive cases (Pizzocaro et al. 2010). In our 
study, indications for pelvic lymph node dissection were 
> 2 proven inguinal metastases, involvement of the femoral 
(Cloquet’s) node, and radiological suspicion of pelvic lymph 
node involvement. Follow-up was by a combination of phys-
ical examination and imaging based on risk stratification 
and was updated by recall to the clinic. Theoretical adher-
ence to the EAU guidelines for primary surgery and lym-
phadenectomy was assessed for each case. A case was con-
sidered adherent when the surgical approach was perfectly 
aligned with the guidelines. For non-adherent cases, reasons 
for discrepancy were analysed and grouped as follows: (1) 
patient’s choice; (2) surgeon’s preference; and (3) other. Sta-
tistical analysis was performed using SPSS (version 25.0). 
Data evaluation confirmed a non-normal distribution of the 
study dataset. Intergroup differences in medians for quanti-
tative variables were tested using the Kruskal–Wallis one-
way analysis of variance, and differences in distributions for 
categorical variables were calculated with a Chi square test. 
Using multiple logistic regression with the ENTER method, 
the statistically significant age-adjusted variables as assessed 
by univariate analysis were entered and investigated as pre-
dictors of adherence to the EAU guidelines. The threshold 
for significance was set at alpha = 0.05. Data are presented as 
mean ± standard deviation (SD). Odds ratios and 95% con-
fidence interval (CI) were calculated for the parameters in 
each group using “non-adherence” as the reference group.
Results
Patients’ demographics, surgical details, and histopathologi-
cal findings are reported in Table 1. Overall, 176 patients 
were enrolled (mean age 66 ± 11.3). All patients had histo-
pathologically confirmed squamous cell carcinoma of the 
penis. Tumours were mainly located at the glans (55%), 38% 
were stage pT1, and 83% had negative surgical margins. 
Penile partial amputation was the most common surgical 
approach (39%). At diagnosis, 30.1% of patients had palpa-
ble inguinal lymph nodes. ILND was performed in 45.1% 
of patients (15% cN0 and 80% cN1/cN2; the remaining 5%, 
although meeting the EAU criteria, declined surgery). Nodal 
status was available for 74 patients: 32 patients were pN0, 19 
were pN1, and 23 were pN2. For primary treatment, adher-
ence to the EAU guidelines was good (66%) (Fig. 1). In 
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non-adherent cases, reasons for discrepancy were patient’s 
choice (17%), surgeon’s preference (36%), and other causes 
(47%) (Table 2). For lymph node treatment, guideline adher-
ence was 70% (Fig. 2), with either patient’s or surgeon’s 
choice or other causes accounting for discrepancy in 28, 20, 
and 25% of non-adherent cases, respectively (Table 2). Uni-
variate analysis showed no significant differences between 
adherent and non-adherent patients, whereas at multivariate 
analysis, the stage appeared to be the only predictor of adher-
ence for primary treatment (OR 2.61, 95% CI 1.34–5.06, 
p = 0.005) (Table 3). At a mean follow-up of 2 years, 126 
patients were alive, 35 had died from cancer progression, 
and the remaining 15 had died of other causes.
Discussion
Clinical guidelines provide scientifically informed guidance 
to both physicians and patients for making appropriate health 
care decisions. They have the potential to improve outcomes, 
enhance consistency of practices across institutions, and 
support quality improvement activities (Heins et al. 2016; 
Catalona 1988). The European Association of Urology con-
stantly produces and updates guidelines covering all fields 
of urology. The EAU guidelines on PC were first published 
in 2001 and received a major update in 2009, concurrently 
with the release of a new version of the TNM Classification 
of Malignant Tumors (TNM). Although most urologists are 
familiar with the EAU recommendations, adherence may 
be poor for several reasons. First of all, penile cancer is a 
rare disease in industrialised countries, which means that 
the approved guidelines are mostly based on small, meth-
odologically weak studies (e.g., retrospective studies, opin-
ion letters, case reports etc.). As a consequence, they will 
have a low level of evidence and degree of recommenda-
tion. Numerous factors may influence adherence in clinical 
practice. Although treatment of the primary tumour can be 
curative for PC, guideline recommendations are not always 
followed, especially when a generally poor prognosis and a 
Fig. 1  Adherence distribution based on pT stages
Table 1  Patients’ demographics: clinical, surgical and pathological 
characteristics (N = 176)
N %




 Cardiovascular disease 16 9
 Dyslipidaemia 8 4.5
 Multiple comorbidities 22 12.5



































 Local excision 42 24
 Glansectomy 27 15.3
 Partial penectomy 69 38.9
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high rate of serious side effects are expected (Leone et al. 
2017; Pizzocaro and L Piva 1988; Breen et al. 2015). For 
example, physicians may be less likely to adhere to estab-
lished treatment recommendations when patients have severe 
comorbidities or poor general health. In our study, treatment 
of the primary tumour was in line with the guidelines in 
66% of cases, with stage being the only significant predictor 
of adherence (OR 2.61, 95% CI 1.34–5.06, p = 0.005). Not 
surprisingly, physicians are more likely to follow procedures 
with which they are more familiar. Nowadays, PC is not 
a topic of frequent discussion in clinical practice (Cabana 
et al. 1999). It is also an emotive disease and both under- and 
overtreatment can have considerable short- and long-term 
repercussions (Kumar et al. 2012). The patient is actively 
involved in the clinical decision-making process, perhaps 
even more so than for any other kind of tumour given the 
potentially devastating effects on quality of life and men-
tal well-being. Our data confirm that the wider discrepancy 
between guidelines and clinical practice is typical of local-
ised tumours that in theory should be better treated with 
organ-preserving techniques. It is worth noting that there 
currently is no widespread definition of penile sparing sur-
gery. Historically, treatment was by radical or partial ampu-
tation with a 2-cm margin for oncologic efficacy. Over time, 
guidelines began to favour a more conservative approach 
whenever possible. Local recurrence has a minimal impact 
on long-term survival. Horenblas et al.’s multivariate analy-
sis demonstrated no difference in cancer-specific survival 
for patients treated with penile sparing surgery vs. partial 
amputation (Djajadiningrat et al. 2004). Despite current 
trends, some less experienced centres continue to have an 
all-too radical approach which is not in line with the lat-
est guidelines. A more extensive experience in treating PC 
would doubtlessly allow for the safer use of conservative 
techniques.
Our study was not geared to describe reasons for non-
adherence in detail, but individual choice appears to be an 
important factor for both patients (24%) and physicians 
(34%), the latter often mentioning lack of training and skill 
as the reason for departing from recommendations. In the 
remaining 42% of cases, we were unable to establish the 
exact reasons for non-compliance. The EAU guidelines 
recommend ILND in cN0 patients with pT1b and T2–T4 
tumours, as well as in all cN1/cN2 patients. Despite lymph 
node status being the primary determinant of survival in 
penile carcinoma (D’Ancona et al. 2004), only a fraction 
of patients who are candidates for ILND undergo the pro-
cedure. Our results indicate an overall ILND rate of 45.1%, 
Table 2  Adherence rates for primary treatment and lymphadenec-





N % N %
Yes 116 65.7 122 69.7
No 60 34.3 54 30.3
Surgeon’s choice 22 35.6 11 20
Patient’s choice 10 17 16 28
Other causes 28 47.5 27 52
Fig. 2  Adherence distribution based on pN stages
Table 3  Population’s 
characteristics based on 
the 2016 EAU guidelines; 







Age (years) [mean (SD)] 68.3 (11.2) 65.5 (11.2) 0.113
Size (cm) [mean (SD)] 3 (2.3) 3 (1.65) 0.387
Circumcision (%) (missing = 16) 21/53 (13.1%) 48/107 (30%) 0.324
PT stage (%)
 Tis–T1a 41/60 (23.4%) 53/115 (30.3%) 0.004
 T1a–T4 19/60 (10.9%) 62/115 (35.4%)
PN stage (%)
 N0 8/17 (10.8%) 24/57 (32.4%) 0.741
 N1 5/17 (6.8%) 14/57 (18.9%)
 N2 4/17 (5.4%) 19/57 (25.7%)
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a figure consistent with previous estimates (ILND ranges 
39.1–43.6%, for all SCC stages) (Ficarra et al. 2005; Ornel-
las et al. 2008). Adherence to the EAU ILND guidelines 
was 70% in our study. This is surprisingly high, even admit-
ting that clinical practice should strive for maximum corre-
spondence with international recommendations. The result 
is also in sharp contrast with the findings by Leijte et al., 
whose analysis of compliance with the NCI ILND guidelines 
reported adherence rates of only 27.6% (Leijte et al. 2008). 
Non-adherence may be ascribed to lack of surgical experi-
ence or insufficient familiarity with inguinal lymphadenec-
tomy. Practical constraints may also have a part, for example, 
in the non-ubiquitous availability of sentinel node biopsies.
Our study is not devoid of limitations. First, its retrospec-
tive design limits the quality of the data. Second, a central 
pathology review could have contributed to higher accuracy 
of pathologically assessed variables, and hence the lack of 
it may represent another weakness. However, none of the 
previously reported multi-institutional studies relied on 
central pathology (Leijte et al. 2008). Third, complications 
and length of hospitalisation could not be analysed because 
the database was not designed to take these parameters into 
account. Fourth, the small number of patients limited deep 
survival analysis, which is important for future research. 
Finally, our study cohort originates from eight European 
centres, each with its own definition of disease progression 
and varying levels of surgical skills. Despite this obvious 
limitation, all multicentre studies benefit from greater gen-
eralisability of results, which increases proportionally to the 
number of surgeons and clinical sites involved.
Conclusion
Adherence to the EAU guidelines for PC was quite good, 
both for treatment of the primary tumour and for ILND. New 
strategies for further improvement may be key to ensuring 
better care in terms of quality and efficacy. These include 
specific surgical training and the formation of super-regional 
networks with a multidisciplinary approach that will likely 
favour high-volume centres.
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